Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
2005-002011-24
Type of Stem Cell Treatment:
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Short title:
RICMAC
Primary objective:
The hypothesis that dose-reduces conditioning will reduce the non-rela'se mortality for 40% to 20% at one year after allogeneic stem cell transplantation​
Key inclusion criteria:
18-65 years old
Country:
Belgium
Finland
France
Germany
Italy
Russian Federation
Switzerland
Principal investigator:
Nicolaus Kröger
EBMT Study coordinator:
Ruzena Uddin